Metabolic Disease Drug Development

Tuesday, October 23 – Thursday, October 25 2012

Location: Hyatt Regency Boston, One Avenue de Lafayette, Boston, Massachusetts 02111

Expanding epidemic. Unmet medical need. Enormous market potential.

Where will innovation come from in the metabolic drug pipeline? What clinical strategies will satisfy regulators?

Answering these questions holds the key to dominating the enormous and expanding cardiometabolic market.

Continuing unmet medical need, bottlenecks in the pipeline and a harsh regulatory climate remain strong drivers for enhancing your metabolic drug development strategy.

By giving you unparalleled access to the minds behind the most promising drugs in development, Metabolic Disease Drug Development will provide the perfect platform to address these concerns and direct your preclinical and clinical development strategy.

Metabolic Disease Drug Development guarantees strong representation and candid discussion from senior level figures at Pfizer, Merck, BMS and the most innovative biotechs in the field. It will provide valuable insight into identifying and validating new metabolic drug targets, streamlining clinical strategy and speeding the passage of your drugs to market.

MassBio members are eligible for a 10% discount off the registration fee. Simply quote ‘MASSBIO’ when registering:

Share MassBio